PTEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PTEN is not a good buy right now. The chart trend is constructive, but it’s extended short-term (RSI elevated and price sitting just below nearby resistance), while fundamentals and positioning signals are mixed (sharp YoY deterioration in the latest quarter and heavy insider selling). With no Intellectia buy signals today and earnings approaching on 2026-02-04 (AH) with an expected loss, the risk/reward for an impatient buyer at $7.47 is not attractive.
Trend/structure is bullish: moving averages are stacked positively (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is above zero and expanding (0.0197), confirming upward momentum. However, RSI_6 at ~72.7 suggests the stock is getting stretched/overbought in the very near term, which often precedes consolidation or a pullback. Key levels: pivot 7.384 is the immediate line in the sand; a hold above it keeps the uptrend intact. Overhead resistance is close at R1 7.71 (then R2 7.912), meaning upside from here is nearer-term capped unless it breaks out cleanly. Support sits at S1 7.057 (then S2 6.855). Pattern-based forward look suggests only modest drift higher over 1W/1M (+1.39% / +1.88%), not a strong immediate breakout profile.
Technicals are supportive (bullish MA stack; MACD strengthening). Hedge fund activity is a tailwind: hedge funds are net buying, with buying amount up ~186% QoQ. Potential event catalyst: QDEC 2025 earnings on 2026-02-04 after hours could re-rate shares if margins/utilization improve beyond expectations.
Fundamentals weakened materially in the latest reported quarter (2025/Q3): revenue -13.36% YoY, EPS -0.10 (down ~96% YoY), net income deteriorated to a loss, and gross margin compressed sharply (reported as 4.81 with a large YoY decline). Insider activity is a major red flag: insiders are selling aggressively (selling amount up ~1148% MoM). No supportive news flow in the last week, so there’s no fresh narrative catalyst to justify chasing strength. Earnings is near-term binary risk, and the Street’s expected EPS is still negative (Est: -0.12).
Latest quarter: 2025/Q3. Revenue fell to ~$1.176B (-13.36% YoY). Profitability deteriorated: net income was -$36.4M (down ~96% YoY) and EPS was -$0.10 (down ~96% YoY). Gross margin weakened significantly (reported 4.81 with a steep YoY decline). Overall, the quarter shows contracting top-line and worsening profitability—an unfavorable backdrop for buying strength without a clear inflection catalyst.
Recent trend is mixed to slightly negative: JPMorgan (2025-12-10) downgraded to Underweight and cut PT to $6 (from $7) on upstream spending headwinds and a cautious oilfield-services outlook. Morgan Stanley assumed with Equal Weight and PT $6.50 (2025-12-15), then modestly raised PT to $7 (2026-01-21) while keeping Equal Weight. Wall Street pros: some stabilization expectations and modest PT lift from MS; cons: a notable downgrade from JPM, concerns about constrained North American onshore spending, and limited conviction reflected by ‘Equal Weight’ rather than a buy rating.
